Anti-inflammatory effects of Tat-Annexin protein on ovalbumin-induced airway inflammation in a mouse model of asthma

Biochemical and Biophysical Research Communications

Volumn 417, Issue 3, 2012, Pages 1024-1029

  Lee, Sun Hwa ^a   Kim, Dae Won ^a   Kim, Hye Ri ^a   Woo, Su Jung ^a   Kim, So Mi ^a   Jo, Hyo Sang ^a   Jeon, Seong Gyu ^b   Cho, Sung Woo ^c   Park, Jong Hoon ^d   Won, Moo Ho ^e   Park, Jinseu ^a   Eum, Won Sik ^a   Choi, Soo Young ^a  

^a Hallym University   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Sookmyung Women's University   (South Korea)

^e Kangwon National University   (South Korea)

Author keywords

Asthma; Cytokine; MAPK; Protein therapy; Tat Annexin 1

Indexed keywords

ANNEXIN; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OVALBUMIN; STRESS ACTIVATED PROTEIN KINASE; TAT ANNEXIN 1 PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DOSE RESPONSE; ENZYME ACTIVATION; EOSINOPHIL; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LUNG FLUID; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION;

ANIMALS; ANNEXIN A1; ANNEXINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE PRODUCTS, TAT; MICE; MICE, INBRED BALB C; OVALBUMIN; RECOMBINANT FUSION PROTEINS;

ANIMALIA; MUS;

EID: 84862792743     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.084     Document Type: Article

References (35)

1. Busse W.W., Lemanske R.F. Asthma. N. Engl. J. Med. 2001, 344:350-362.
2. Wills-Karp M. Immunologic basis of antigen-induced airway hyper-responsiveness. Annu. Rev. Immunol. 1999, 17:255-281.
3. Munroe M.E., Businga T.R., Kline J.N., et al. Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma. J. Immunol. 2010, 185:5586-5597.
4. Herrick C.A., Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol. 2003, 3:405-412.
5. Nakajima H., Takatsu K. Role of cytokines in allergic airway inflammation. Int. Arch. Allergy Immunol. 2007, 142:265-273.
6. Wynn T.A. IL-13 effector functions. Annu. Rev. Immunol. 2003, 21:425-456.
7. Kips J.C. Cytokines in asthma. Eur. Respir. J. (Suppl.) 2001, 34:24s-33s.
8. Rosenberg H.F., Phipps S., Foster P.S. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 2007, 119:1303-1310.
9. Rose-John S., Waetzig G.H., Scheller J., et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 2007, 11:613-624.
10. Russo C., Polosa R. TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin. Sci. 2005, 109:135-142.
11. Chang L., Karin M. Mammalian MAP kinase signaling cascades. Nature 2001, 410:37-40.
12. Chung W.Y., Park J.H., Kim M.J., et al. Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-kB. Carcinogenesis 2007, 28:1224-1231.
13. Ho Y.S., Lai C.S., Liu H.I., et al. Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation. Biochem. Pharmacol. 2007, 73:1786-1795.
14. Duan W., Chan J.H.P., Wong C.H., et al. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J. Immunol. 2004, 172:7053-7059.
15. Kumar A., Lnu S., Malya R., et al. Mechanical stretch activates nuclear factor-kB, activator protein-1, and mitogen-activated protein kinases in lung parnchyma: implications in asthma. FASEB J. 2003, 17:1800-1811.
16. Babbin B., Laukoetter M.G., Nava P., et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J. Immunol. 2008, 181:5035-5044.
17. Kamal A.M., Flower R.J., Perretti M. An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem. Inst. Oswaldo Cruz Rio de Janeiro 2005, 100(Suppl. 1):39-48.
18. Perretti M., D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rew. Immunol. 2009, 9:62-70.
19. Wadia J., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 2002, 13:52-56.
20. Ahn E.H., Kim D.W., Kang H.W., et al. Transduced PEP-1-ribosomal protein S3 (rpS3) ameliorates 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Toxicology 2010, 276:192-197.
21. An J.J., Lee Y.P., Kim S.Y., et al. Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J. 2008, 275:1296-1308.
22. Choi H.S., An J.J., Kim S.Y., et al. PEP-1-SOD fusion protein efficiently protects against paraquat-induced dopaminergic neuron damage in a Parkinson disease mouse model. Free Radic. Biol. Med. 2006, 41:1058-1068.
23. Kim D.W., Jeong H.J., Kang H.W., et al. Transduced PEP-1-catalase fusion protein attenuates ischemic neuronal damage. Free Radic. Biol. Med. 2009, 47:941-952.
24. Lee S.H., Kim D.W., Back S.S., et al. Transduced Tat-annexin protein suppresses inflammation-associated gene expression in lipopolysaccharide (LPS)-stimulated Raw 264.7 cells. BMB Rep. 2011, 44:484-489.
25. 2+ signaling to membranes dynamics. Nat. Rew. Mol. Cell Biol. 2005, 6:449-461.
26. Parente L., Solito E. Annexin1: more than anti-phospholipase protein. Inflamm. Res. 2004, 53:125-132.
27. Chung Y.W., Oh H.Y., Kim J.Y., et al. Allergen-induced proteolytic cleavage of annexin-1 and activation of cytosolic phospholipase A2 in the lungs of a mouse model of asthma. Proteomics 2004, 4:3328-3334.
28. Elias J.A., Lee C.G., Zheng T., et al. New insights into the pathogenesis of asthma. J. Clin. Invest. 2003, 111:291-297.
29. Taube C., Duez C., Cui Z.H., et al. The role of IL-13 in established allergic airway disease. J. Immunol. 2002, 169:6482-6489.
30. Foster P.S., Hogan S.P., Ramsay A.J., et al. Interleukin 5 deficiency abolishes eosinophila, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 1996, 183:195-201.
31. Kopf M., Le Gros L.G., Bachmann M., et al. Disruption of the murine IL-4 gene blocks Th2 cytokine response. Nature 1993, 362:245-248.
32. Bradford M.A. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
33. Kim Y.K., Oh S.Y., Jeon S.G., et al. Airway exposure levels of lipopolysaccharide determine type 1 versus type 2 experimental asthma. J. Immunol. 2007, 178:5375-5382.
34. Lee K.S., Lee H.K., Hayflick J.S., et al. Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 2006, 20:455-465.
35. Zhu Z.R., Homer J., Wang Z., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 1999, 103:779-788.